Mesoblast

Mesoblast is a biotechnology company that is developing and commercializing allogeneic cellular therapeutics to treat serious and life-threatening inflammatory diseases with high unmet medical needs.

The following are the Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates:

• RYONCIL (remestemcel-L) is used to treat steroid-resistant acute graft versus host disease (acute GVHD).
• Remestemcel-L for COVID-19 infection-related mild to severe acute respiratory distress syndrome (ARDS).
• REVASCOR is used to treat advanced chronic heart failure, while MPC-06-ID is used to treat chronic low back pain caused by degenerative disc degeneration.

Mesoblast's product development strategy is to conduct rigorous scientific studies using well-characterized cell populations in order to identify mechanisms of action for each potential application. Mesoblast has an extensive patent portfolio that includes over 1,000 patents and patent applications with protection in all key markets through 2040. This intellectual property portfolio includes mesenchymal lineage cell composition, production, and medicinal uses.

Founded: 2004

Headquarters: Melbourne, VIC, Australia

Website: https://www.mesoblast.com/